SynthesisDiagnostic and interventional radiology (Ankara, Turkey)
Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?
Synthesis in Diagnostic and interventional radiology (Ankara, Turkey). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Unique magnetic resonance spectroscopy profile of intracranial meningiomas compared to gliomas: a systematic review.Acta neurologica Belgica · 2023Pooled it
- Multi-Vendor and Multi-Site Characterization ofMagnetic resonance in medicine · 2026Article
- Diagnostic Accuracy ofJournal of magnetic resonance imaging : JMRI · 2025Article
- DKI andBMC medical imaging · 2024Article
- The Use of Magnetic Resonance Imaging in Radiation Therapy Treatment Simulation and Planning.Journal of magnetic resonance imaging : JMRI · 2024Review
- Review
- Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment.NPJ precision oncology · 2024Review
- Small molecule metabolites: discovery of biomarkers and therapeutic targets.Signal transduction and targeted therapy · 2023Review
- The contribution of theEuropean radiology experimental · 2022Article
- Revisiting the use of proton magnetic resonance spectroscopy in distinguishing between primary and secondary malignant tumors of the central nervous system.The neuroradiology journal · 2022Article
- Metabolic Alterations in Sputum and Exhaled Breath Condensate of Early Stage Non-Small Cell Lung Cancer Patients After Surgical Resection: A Pilot Study.Frontiers in oncology · 2022Article
- Metabolic Alterations in Pancreatic Cancer Detected by In VivoDiagnostics (Basel, Switzerland) · 2021Article
- Imaging biomarkers for evaluating tumor response: RECIST and beyond.Biomarker research · 2021Review
- Metabolic Changes in Early-Stage Non-Small Cell Lung Cancer Patients after Surgical Resection.Cancers · 2021Article
- What is the optimal schedule for multiparametric MRS? A magnetic resonance fingerprinting perspective.NMR in biomedicine · 2021Article
- Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2021Article
- ADNEX Model-Based Diagnosis of Ovarian Cancer Using MRI Images.Contrast media & molecular imaging · 2021Article
- Non-invasive exploration of metabolic profile of lung cancer with Magnetic Resonance Spectroscopy and Mass Spectrometry.Contemporary clinical trials communications · 2019Article
- How clinical imaging can assess cancer biology.Insights into imaging · 2019Review
- Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer.European radiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abnormal metabolism is a key tumor hallmark. Proton magnetic resonance spectroscopy (1H-MRS) allows measurement of metabolite concentration that can be utilized to characterize tumor metabolic changes. 1H-MRS measurements of specific metabolites have been implemented in the clinic. This article performs a systematic review of image acquisition and interpretation of 1H-MRS for cancer evaluation, evaluates its strengths and limitations, and correlates metabolite peaks at 1H-MRS with diagnostic and prognostic parameters of cancer in different tumor types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.